Inclisiran: Clinical Trials

43 trials of Inclisiran, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 11 recruiting, 8 active not recruiting, 3 not yet recruiting. 16 Phase 3, 10 Phase 4, 3 Phase 2, 2 Not applicable, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 316Completed 9, Recruiting 4, Active not recruiting 3
Phase 410Not yet recruiting 3, Active not recruiting 2, Recruiting 2, Completed 1, Unknown 1, Withdrawn 1
Phase 23Completed 2, Recruiting 1
Not applicable2Completed 1, Recruiting 1
Phase 11Completed 1

Follow Inclisiran: new trials by email Literature Review of Inclisiran trials Research Report on Inclisiran

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome
Inclisiran, Atorvastatin or Rosuvastatin, Ezetimibe - Acute Coronary Syndromes (ACS)
Phase 4Not yet recruitingSeoul National University Bundang Hospital2942026-11-302026-11-18
Comparing Inclisiran Versus Statin for Primary Aldosteronism
inclisiran, Lipophilic statins (such as Simvastatin, Atorvastatin, Fluvastatin, Lovastatin,Pitavastatin), Spironolactone (drug) - Primary Aldosteronism
Not applicableRecruitingThird Military Medical University502026-11-152026-11-12
Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
inclisiran, SOC - Acute Coronary Syndrome
Phase 4Not yet recruitingNovartis Pharmaceuticals3002026-10-312026-10-30
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
QCZ484, Inclisiran, QCZ484 placebo - Hypercholesterolaemia
Phase 2RecruitingNovartis Pharmaceuticals1202026-05-292026-07-30
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
Inclisiran, Alirocumab - Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD)
Phase 4RecruitingUniversity Medical Centre Ljubljana602026-05-182026-06-02
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Placebo, Inclisiran - Acute Coronary Syndrome
Phase 3Active not recruitingNovartis Pharmaceuticals3052025-10-032026-11-17
Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
Inclisiran - Primary Hypercholesterolemia or Mixed Dyslipidemia
RecruitingNovartis Pharmaceuticals15002025-08-132025-12-22
Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study
Inclisiran - Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia
Active not recruitingNovartis Pharmaceuticals2192025-06-162026-08-07
Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice
Alirocumab 150 mg, Inclisiran - Atherosclerotic Cardiovascular Disease
CompletedSanofi9962025-05-222026-10-13
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Pelacarsen, Placebo, Inclisiran - Atherosclerotic Cardiovascular Disease (ASCVD)
Phase 3Active not recruitingNovartis Pharmaceuticals2462025-04-302026-10-14
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Atorvastatin, Simvastatin, Rozuvastatin - Atherosclerotic Cardiovascular Disease
RecruitingNovartis Pharmaceuticals23822025-04-152026-11-13
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Inclisiran, Placebo - Familial Hypercholesterolemia - Homozygous
Phase 3RecruitingNovartis Pharmaceuticals92025-02-282026-07-24
LATAM LOWERS LDL-C
Usual care, KJX839 - Hypercholesterolaemia
Phase 4RecruitingNovartis Pharmaceuticals5202025-02-112025-12-30
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
Inclisiran - Atherosclerotic Cardiovascular Disease
Phase 4Active not recruitingDuke University1302024-12-162026-07-29
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Inclisiran, Placebo - Familial Hypercholesterolemia - Heterozygous
Phase 3RecruitingNovartis Pharmaceuticals602024-12-092026-05-15
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
inclisiran - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 4CompletedNovartis Pharmaceuticals652024-11-122026-06-23
Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound
Inclisiran - Carotid Plaque, Hyperlipidemia
Phase 4UnknownFirst Affiliated Hospital of Xinjiang Medical University402024-09-202024-09-19
The Prevent Coronary Artery Disease Trial
Inclisiran - Atherosclerotic Cardiovascular Disease
Phase 3RecruitingIcahn School of Medicine at Mount Sinai16002024-09-122025-04-29
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
atorvastatin, IVUS/OCT, inclisiran - Plaque, Atherosclerotic
Phase 4Active not recruitingNovartis Pharmaceuticals3182024-07-092026-07-28
Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart Disease
Inclisiran - Ischemic Heart Disease, Acute Coronary Syndrome
Phase 4Not yet recruitingJose Seijas Amigo502024-06-012024-05-20

Showing 20 of 43. Sign in to see all of them.

Conditions studied

Atherosclerosis (20)  ·  Hypercholesterolemia (16)  ·  Hyperlipidemias (8)  ·  Hyperlipoproteinemia Type II (7)  ·  Acute Coronary Syndrome (5)  ·  Cardiovascular Diseases (4)  ·  Homozygous Familial Hypercholesterolemia (4)  ·  Plaque, Atherosclerotic (3)  ·  Aortic Valve Stenosis (2)  ·  Dyslipidemias (2)  ·  Heart Failure (2)  ·  Carotid Stenosis (1)  ·  Coronary Artery Disease (1)  ·  Diabetes Mellitus (1)  ·  Hyperaldosteronism (1)

Sponsors

Novartis Pharmaceuticals (26)  ·  The Medicines Company (3)  ·  Duke University (1)  ·  Federico II University (1)  ·  First Affiliated Hospital of Xinjiang Medical University (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Jose Seijas Amigo (1)  ·  LIB Therapeutics LLC (1)  ·  Pauls Stradins Clinical University Hospital (1)  ·  Sanofi (1)  ·  Seoul National University Bundang Hospital (1)  ·  Third Military Medical University (1)  ·  University Medical Centre Ljubljana (1)  ·  University of Cambridge (1)  ·  University of Louisville (1)

Countries

United States (18)  ·  United Kingdom (12)  ·  Germany (11)  ·  China (9)  ·  Netherlands (9)  ·  Spain (9)  ·  Canada (7)  ·  France (7)  ·  Malaysia (6)  ·  Greece (5)  ·  Hungary (5)  ·  Italy (5)  ·  South Africa (5)  ·  Taiwan (5)  ·  Turkey (Türkiye) (5)

Top investigators

David Preiss (1)  ·  Dinesh Kalra, MD (1)  ·  Evan A Stein, MD PhD (1)  ·  Frederick J. Raal, MD (1)  ·  Jan Kafol, MD (1)  ·  Jason M Tarkin, MBBS PhD (1)  ·  Karlis Trusinskis, MD (1)  ·  Kausik K Ray, MD (1)  ·  Kausik Ray, MD (1)  ·  Louise Bowman (1)  ·  Marion Mafham (1)  ·  Neha Pagidipati, MD (1)  ·  Richard Robson, PhD (1)  ·  Valentin Fuster, MD, PhD (1)

Results publications

PMID 33990512, PMID 31630870, PMID 35175352, PMID 38063346, PMID 28306389, PMID 29735484, PMID 30487231, PMID 31553410, PMID 32197277, PMID 36620965, PMID 38593947, PMID 38757725, PMID 39053958, PMID 40010816, PMID 40391436, PMID 40392667, PMID 41604274, PMID 41616799, PMID 42132192, PMID 42567431

NIH funding

2016 (1), 2017 (1), 2025 (1)